Jeeyun Lee

Joon-Oh Park, Jeeyun Lee, Hi-Bahl Lee, 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer.

Su Jin Lee, S. J. Lee, Joon-Oh Park, 2017, Journal of geriatric oncology.

A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology

Joon-Oh Park, Hyo Song Kim, S. Park, 2015, Cancer research and treatment : official journal of Korean Cancer Association.

Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer

Joon-Oh Park, S. Park, Kyoung-Mee Kim, 2014, Scientific Reports.

A phase I/II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer

Joon-Oh Park, Hyo Song Kim, S. Park, 2009, Cancer Chemotherapy and Pharmacology.

Results from the safety interim analysis of the adjuvant chemoradiotherapy in stomach tumors 2 trial: a multicenter, randomized phase III clinical trial

Su Jin Lee, S. J. Lee, Joon-Oh Park, 2019, Precision and Future Medicine.

Phase I study of neoadjuvant chemoradiotherapy with S-1 and oxaliplatin in patients with locally advanced gastric cancer

Joon-Oh Park, S. Park, Kyoung-Mee Kim, 2012, Cancer Chemotherapy and Pharmacology.

BroadDetectionofAlterationsPredicted toConfer LackofBenefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer

Philip, Siraj, James, 2016 .

A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer

S. Choi, J. K. Lee, Joon-Oh Park, 2006, Journal of gastroenterology and hepatology.

The Role of Plasma Chromogranin A as Assessment of Treatment Response in Non-functioning Gastroenteropancreatic Neuroendocrine Tumors

Joon-Oh Park, S. Park, Jeeyun Lee, 2015, Cancer research and treatment : official journal of Korean Cancer Association.

Gastroenteropancreatic neuroendocrine tumors: Incidence and treatment outcome in a single institution in Korea

S. Choi, D. Choi, J. K. Lee, 2011, Asia-Pacific journal of clinical oncology.

Combination chemotherapy with paclitaxel and ifosfamide as the third-line regimen in patients with heavily pretreated small cell lung cancer.

Joon-Oh Park, J. Ahn, M. Ahn, 2007, Lung cancer.

Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases in Korea: A Clinicopathological Analysis of 72 Cases in a Single Institute

C. Park, Kyoung-Mee Kim, K. Jang, 2015, Cancer research and treatment : official journal of Korean Cancer Association.

Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study

Su Jin Lee, S. J. Lee, S. Park, 2017, Journal of gynecologic oncology.

A Korean single-center, real-world, retrospective study of first-line weekly paclitaxel in patients with metastatic angiosarcoma

Su Jin Lee, S. J. Lee, S. Park, 2016, Clinical Sarcoma Research.

Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide

Jin-Hee Ahn, Jeeyun Lee, S. Rha, 2013, Investigational New Drugs.

Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients

Su Jin Lee, S. J. Lee, Joon-Oh Park, 2013, Investigational New Drugs.

P21-activated kinase 4 overexpression in metastatic gastric cancer patients.

Joon-Oh Park, Kyoung-Mee Kim, Jeeyun Lee, 2011, Translational oncology.

A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer.

Joon-Oh Park, S. Park, Jeeyun Lee, 2010, European journal of cancer.

Treatment of Hemodialyzed Patients with Sunitinib in Renal Cell Carcinoma

Jin Hyun Cho, Joon-Oh Park, S. Park, 2010, Chemotherapy.

A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer

Joon-Oh Park, Hyo Song Kim, S. Park, 2009, BMC Cancer.

Direct analysis of aberrant glycosylation on haptoglobin in patients with gastric cancer

S. J. Lee, Joon-Oh Park, S. Park, 2016, Oncotarget.

IL-7Rαlow CD8+ T Cells from Healthy Individuals Are Anergic with Defective Glycolysis

I. Kang, Kyoung-Mee Kim, E. Choi, 2020, The Journal of Immunology.

Gastrointestinal malignancies harbor actionable MET exon 14 deletions

Joon-Oh Park, H. Kim, S. Ou, 2015, Oncotarget.

Detecting Gene Rearrangements in Patient Populations Through a 2-Step Diagnostic Test Comprised of Rapid IHC Enrichment Followed by Sensitive Next-Generation Sequencing

R. Shoemaker, Kyoung-Mee Kim, Jeeyun Lee, 2016, Applied immunohistochemistry & molecular morphology : AIMM.

NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line

Woo, Joon, Zachary, 2015, Oncotarget.

Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target.

Joon-Oh Park, C. Ki, S. Park, 2011, Oncology reports.

Predictive value of the ERCC1 expression for treatment response and survival in advanced gastric cancer patients receiving cisplatin-based first-line chemotherapy.

Joon-Oh Park, S. Park, Kyoung-Mee Kim, 2010, Cancer research and treatment : official journal of Korean Cancer Association.

Clinical Outcome of Gastric Cancer Patients with Bone Marrow Metastases

Joon-Oh Park, Hee-Jin Kim, Hyo Song Kim, 2008, Oncology.

The Impact of Tumor Mutation Burden on the Effect of Frontline Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric Cancers

Jeeyun Lee, H. Lim, S. Kim, 2021, Frontiers in Oncology.

Association of serine/threonine kinase 11 mutations and response to programmed cell death 1 inhibitors in metastatic gastric cancer.

Kyoung-Mee Kim, Jeeyun Lee, S. Kim, 2020, Pathology, research and practice.

The impact of pathologic differentiation (well/poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs

Joon-Oh Park, S. Park, Jeeyun Lee, 2017, Oncotarget.

A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma

Joon-Oh Park, S. Park, K. Koh, 2009, Cancer Chemotherapy and Pharmacology.

Nomogram to Predict Treatment Outcome of Fluoropyrimidine/Platinum-Based Chemotherapy in Metastatic Esophageal Squamous Cell Carcinoma

Y. Shim, S. Park, Y. Im, 2013, Cancer research and treatment : official journal of Korean Cancer Association.

Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study

R. Cristescu, J. Yearley, Xiao Qiao Liu, 2022, Journal for ImmunoTherapy of Cancer.

When to apply immune checkpoint inhibitor in patients with refractory advanced gastric cancer

Jeeyun Lee, H. Lim, S. Kim, 2021, Journal of Cancer.

Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era

Su Jin Lee, S. J. Lee, Joon-Oh Park, 2016, Journal of Cancer.

The Clinicopathologic Features and Treatment of 607 Hindgut Neuroendocrine Tumor (NET) Patients at a Single Institution

D. Chang, J. Huh, Y. Park, 2016, Medicine.

Effects of single nucleotide polymorphisms on treatment outcomes and toxicity in patients treated with sunitinib.

Joon-Oh Park, S. Park, Jeeyun Lee, 2013, Anticancer research.

Circulating Tumor Cells are Predictive of Poor Response to Chemotherapy in Metastatic gastric cancer

Su Jin Lee, S. J. Lee, Joon-Oh Park, 2015, The International journal of biological markers.

CD151 Overexpression is Associated with Poor Prognosis in Patients with pT3 Gastric Cancer

Joon-Oh Park, S. Park, Kyoung-Mee Kim, 2014, Annals of Surgical Oncology.

Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer

W. Park, Kyoung-Mee Kim, Jeeyun Lee, 2022, Journal for ImmunoTherapy of Cancer.

Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials.

Y. Bang, C. Fuchs, E. Van Cutsem, 2021, JAMA oncology.

GSTT 1 Copy Number Gain and ZNF Overexpression Are Predictors of Poor Response to Imatinib in Gastrointestinal Stromal Tumors

Joon-Oh Park, E. J. Lee, C. Park, 2013 .

CDH1 mutations in gastric cancers are not associated with family history.

Jong-Won Kim, Kyoung-Mee Kim, Jeeyun Lee, 2020, Pathology, research and practice.

CDH1 mutations in gastric cancers are not influenced by family history

Jong-Won Kim, Kyoung-Mee Kim, Jeeyun Lee, 2020 .

Microsatellite Instability and Effectiveness of Adjuvant Treatment in pT1N1 Gastric Cancer: A Multicohort Study

Yoon Young Choi, J. Cheong, Kyoung-Mee Kim, 2021, Annals of Surgical Oncology.

High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features.

S. Park, R. Cristescu, Kyoung-Mee Kim, 2020, Pathology, research and practice.

Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

Y. Bang, M. Rebelatto, H. Lenz, 2019, Clinical Cancer Research.

Systematic Evaluation of Gastric Tumor Cell Index and Two-Drug Combination Therapy via 3-Dimensional High-Throughput Drug Screening

Jason K. Sa, Dong Woo Lee, Joon-Oh Park, 2019, Front. Oncol..

Development of mesenchymal subtype gene signature for clinical application in gastric cancer

S. Park, R. Cristescu, Kyoung-Mee Kim, 2017, Oncotarget.

Low ATM expression and progression-free and overall survival in advanced gastric cancer patients treated with first-line XELOX chemotherapy.

Kyoung-Mee Kim, Jeeyun Lee, S. Kim, 2018, Journal of gastrointestinal oncology.

VIKTORY trial: Report on AZD1775/paclitaxel in TP53 mutation (+) GC, selumetinib/paclitaxel in ras aberrant GC, AZD5363/paclitaxel in PIK3CA mt and biomarker negative, savolitinib/docetaxel in met (+), and vistusertib/paclitaxel in RICTOR(+) GC.

Joon-Oh Park, S. Park, E. Harrington, 2017 .

Cell free circulating tumor DNA (ctDNA) landscape in patients with advanced gastroesophageal adenocarcinoma (GEC).

E. Kwak, Jeeyun Lee, F. Braiteh, 2017 .

Visceral adiposity and systemic inflammation in the obesity paradox in patients with unresectable or metastatic melanoma undergoing immune checkpoint inhibitor therapy: a retrospective cohort study

Ji Hyun Lee, Jeeyun Lee, S. Hyung, 2022, Journal for ImmunoTherapy of Cancer.

O-11 Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: A randomized, phase 2, multicenter, open-label study (DESTINY-Gastric01)

Y. Bang, N. Sugimoto, D. Sakai, 2020 .

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.

Y. Bang, N. Sugimoto, D. Sakai, 2020, The New England journal of medicine.

LAG3 in Solid Tumors as a Potential Novel Immunotherapy Target

Su Jin Lee, Joon-Oh Park, S. Park, 2019, Journal of immunotherapy.

MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines

Joon-Oh Park, S. Park, Kyoung-Mee Kim, 2017, Oncotarget.

The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors

Joon-Oh Park, S. Park, Kyoung-Mee Kim, 2021, Journal of Cancer Research and Clinical Oncology.

High delta-like ligand 4 expression correlates with a poor clinical outcome in gastric cancer

S. Park, W. You, Kyoung-Mee Kim, 2019, Journal of Cancer.

Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: a double-blind randomised phase 3 study.

Joon-Oh Park, S. Park, I. Hwang, 2014, European journal of cancer.

Lovastatin-induced RhoA modulation and its effect on senescence in prostate cancer cells.

Jeeyun Lee, W. Kang, Inkyoung Lee, 2006, Biochemical and biophysical research communications.

First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF V600-mutant advanced melanoma.

W. Koom, Jeeyun Lee, S. Shin, 2022, Journal of the American Academy of Dermatology.

TP53 alteration determines the combinational cytotoxic effect of doxorubicin and an antioxidant NAC

W. Park, Jeeyun Lee, S. Seo, 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.

Y. Bang, C. Fuchs, E. Van Cutsem, 2020, JAMA oncology.

First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients

Joon-Oh Park, D. Nam, Keunchil Park, 2020, Therapeutic advances in medical oncology.

Homologous Recombination Deficiency as a Novel Therapeutic Target in Various Solid Tumors

Joon-Oh Park, S. Park, Kyoung-Mee Kim, 2021 .

Development of Novel Patient-Derived Preclinical Models from Malignant Effusions in Patients with Tyrosine Kinase Inhibitor–Resistant Clear Cell Renal Cell Carcinoma1

O. Rath, S. Park, W. Park, 2017, Translational oncology.

Palliative chemotherapy for non-transitional cell carcinomas of the urothelial tract

Joon-Oh Park, S. Park, W. Kim, 2009, Medical oncology.

Clinical scoring system for the prediction of survival of patients with advanced gastric cancer

Jong Soo Choi, D. Chang, S. Park, 2020, ESMO Open.

High-level FGFR2 amplification is associated with poor prognosis and Lower response to chemotherapy in gastric cancers.

Kyoung-Mee Kim, Kyung Kim, Jeeyun Lee, 2020, Pathology, research and practice.

Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas

Myung Ah Lee, M. Ahn, Tae-You Kim, 2007, Cancer Chemotherapy and Pharmacology.

Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability-High Gastric Cancer.

W. Park, Kyu-Tae Kim, Kyoung-Mee Kim, 2021, Cancer discovery.

Clinical profile of cutaneous adverse events of immune checkpoint inhibitors in a single tertiary center

S. Oh, Jeeyun Lee, Ji-Hye Park, 2021, The Journal of dermatology.

Belvarafenib, a novel pan-RAF inhibitor, in solid tumor patients harboring BRAF, KRAS, or NRAS mutations: Phase I study.

Tae Won Kim, Jeeyun Lee, Hyeong-Seok Lim, 2019, Journal of Clinical Oncology.

A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma.

S. Park, Young Saing Kim, I. Hwang, 2016, Clinical genitourinary cancer.

Phase I study of intraperitoneal irinotecan in patients with gastric adenocarcinoma with peritoneal seeding

Joon-Oh Park, S. Park, D. Yim, 2010, Cancer Chemotherapy and Pharmacology.

Evaluating Targeted Next-Generation Sequencing (NGS) Assays and Reference Materials for NTRK Fusion Detection.

Weei‐Yuarn Huang, C. B. Chung, Zhaolin Xu, 2021, The Journal of molecular diagnostics : JMD.

The efficacy of frontline platinum-based combination chemotherapy in advanced adenocarcinoma of the ampulla of Vater

S. Choi, D. Choi, J. K. Lee, 2010, Medical oncology.

Cancer Panel Assay for Precision Oncology Clinic: Results from a 1-Year Study

Joon-Oh Park, Kyoung-Mee Kim, K. Jang, 2019, Translational oncology.

Predictive Value of the ERCC 1 Expression for Treatment Response and Survival in Advanced Gastric Cancer Patients Receiving Cisplatin-based First-line Chemotherapy

Joon-Oh Park, S. Park, Kyoung-Mee Kim, 2010 .

Genomic Alterations in Biliary Tract Cancer Using Targeted Sequencing1

Joon-Oh Park, W. Park, W. Kwon, 2016, Translational oncology.

Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma.

Andrew Dunford, Kyoung-Mee Kim, Masayuki Watanabe, 2018, Cancer discovery.

Impact of E2F-1 Expression on Clinical Outcome of Gastric Adenocarcinoma Patients with Adjuvant Chemoradiation Therapy

Joon-Oh Park, C. Park, Kyoung-Mee Kim, 2008, Clinical Cancer Research.

INTEGRATE: A randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): A study by the Australasian Gastrointestinal Trials Group (AGITG)—Final overall and subgroup results.

L. Lipton, N. Pavlakis, Y. Bang, 2015 .

Screening for somatic mutations in esophageal squamous cell carcinoma using OncoMap 4.0.

L. Macconaill, S. Park, P. Hummelen, 2012, Journal of Clinical Oncology.

Effect of leukocyte alteration on treatment outcomes following preoperative chemoradiotherapy in patients with rectal cancer

Tae Gyu Kim, Joon-Oh Park, Y. Cho, 2017, Radiation oncology journal.

ESRP1-regulated isoform switching of LRRFIP2 determines metastasis of gastric cancer

A. Ooshima, Jeeyun Lee, Jinah Park, 2022, Nature Communications.

Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced gastric or gastroesophageal junction cancer from JAVELIN solid tumor phase Ib trial: Analysis of safety and clinical activity.

Sung Sook Lee, B. Melichar, Yoon-Koo Kang, 2016 .

Correlation between RICTOR overexpression and amplification in advanced solid tumors.

Kyoung-Mee Kim, Jeeyun Lee, H. Park, 2019, Pathology, research and practice.

Adjuvant Chemotherapy Versus Chemoradiotherapy Versus Surgery Alone for Early Gastric Cancer with One or Two Lymph Node Metastasis

Jeeyun Lee, T. Sohn, Su Mi Kim, 2018, Annals of surgical oncology.

Accuracy of MRI for estimating residual tumor size after neoadjuvant chemotherapy in locally advanced breast cancer: Relation to response patterns on MRI

J. Ahn, Y. Im, Y. Ko, 2007, Acta oncologica.

Tumor Response to Temsirolimus for Epithelioid Angiomyolipoma and Novel Mutation of SMARCB1/INI1 Tumor Suppressor Gene

Kyoung-Mee Kim, Jeeyun Lee, Sung Kim, 2014 .

A comparison of FOLFIRI (Folinic Acid, Fluorouracil and Irinotecan) Plus Bevacizumab and FLOLFIRI Plus Aflibercept as Second-Line Treatment for Metastatic Colorectal Cancer

Joon-Oh Park, S. Park, Jeeyun Lee, 2020 .

A phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy.

F. Hodi, Y. Bang, P. LoRusso, 2019, Journal of Clinical Oncology.

Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): Results from a phase I study.

J. Ajani, F. Meric-Bernstam, A. El-Khoueiry, 2021 .

Primary malignant melanoma of the uterine cervix treated with pembrolizumab after radical surgery: a case report and literature review

Jeong-Won Lee, Tae-Joong Kim, C. Choi, 2018, Obstetrics & gynecology science.

Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study.

J. Mayordomo, F. Meric-Bernstam, A. El-Khoueiry, 2022, The Lancet. Oncology.

Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer

Joon-Oh Park, S. Park, Kyoung-Mee Kim, 2020, Translational cancer research.

Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer.

Joon-Oh Park, S. Park, J. Cho, 2018 .

Salvage Chemotherapy with Paclitaxel, Ifosfamide, and Cisplatin (TIP) in Relapsed or Cisplatin-Refractory Germ Cell Tumors

Joon-Oh Park, S. Park, Jeeyun Lee, 2011, Oncology Research and Treatment.

Five-gene signature for the prediction of response to immune checkpoint inhibitors in patients with gastric and urothelial carcinomas.

S. Park, Kyoung-Mee Kim, G. Kwon, 2022, Pathology, research and practice.

All‐in‐one microfluidic design to integrate vascularized tumor spheroid into high‐throughput platform

N. Jeon, Jihoon Ko, Jeeyun Lee, 2022, Biotechnology and bioengineering.

A randomized, open‐label clinical trial of tasisulam sodium versus paclitaxel as second‐line treatment in patients with metastatic melanoma

A. Hauschild, A. Arance, C. Garbe, 2014, Cancer.

CD133-positive tumor cell content is a predictor of early recurrence in colorectal cancer.

Joon-Oh Park, H. Kim, Kyoung-Mee Kim, 2014, Journal of gastrointestinal oncology.

Copy Number Gains at 8q24 and 20q11-q13 in Gastric Cancer Are More Common in Intestinal-Type than Diffuse-Type

Joobae Park, Duk-Hwan Kim, Jeeyun Lee, 2015, PloS one.

Early Tumor–Immune Microenvironmental Remodeling and Response to First-Line Fluoropyrimidine and Platinum Chemotherapy in Advanced Gastric Cancer

W. Park, Kyoung-Mee Kim, Jeeyun Lee, 2021, Cancer discovery.

Tumor-promoting macrophages prevail in malignant ascites of advanced gastric cancer

W. Park, Woosung Chung, Hye Hyeon Eum, 2020, Experimental & Molecular Medicine.

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kazuhiro Yoshida, A. Benson, Y. Bang, 2018, The Lancet.

Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition

Jia Qi Lim, A. Jeyasekharan, L. Molinero, 2021, Gut.

Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer

Joon-Oh Park, S. Park, K. Jang, 2021, Oncology.

PD-L1 expression as a prognostic marker in patients with advanced biliary tract cancer.

Joon-Oh Park, S. Park, Jeeyun Lee, 2020 .

Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial

Su Jin Lee, Joon-Oh Park, S. Park, 2018, Journal of gastric cancer.

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

A. Drilon, S. Ou, A. Shaw, 2017, Cancer discovery.

Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients

S. Choi, Joon-Oh Park, S. Park, 2013, Cancer Chemotherapy and Pharmacology.

Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy

Kyoung-Mee Kim, Raul Rabadan, Donggeon Kim, 2018, Nature Genetics.

Comprehensive pharmacogenomic characterization of gastric cancer

Joon-Oh Park, D. Nam, S. Park, 2020, Genome Medicine.

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.

A. Drilon, A. Shaw, S. Ou, 2018, Cancer discovery.

Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype

G. Mills, J. Ajani, Yiling Lu, 2018, Nature Communications.

Comprehensive pharmacogenomic characterization of gastric cancer

Joon-Oh Park, D. Nam, S. Park, 2020, Genome Medicine.

Tumor genomic profiling guides metastatic gastric cancer patients to targeted treatment: The VIKTORY Umbrella Trial.

Joon-Oh Park, S. Park, Young Saing Kim, 2019, Cancer discovery.

Patient-derived cell models as preclinical tools for genome-directed targeted therapy

Joon-Oh Park, O. Rath, S. Park, 2015, Oncotarget.

CCNE1 amplification is associated with liver metastasis in gastric carcinoma.

Kyoung-Mee Kim, K. Jang, Jeeyun Lee, 2019, Pathology, research and practice.

Tumor Heterogeneity Index to Detect Human Epidermal Growth Factor Receptor 2 Amplification by Next-Generation Sequencing: A Direct Comparison Study with Immunohistochemistry.

I. Sohn, Kyoung-Mee Kim, Jeeyun Lee, 2019, The Journal of molecular diagnostics : JMD.

The Impact of Concomitant Genomic Alterations on Treatment Outcome for Trastuzumab Therapy in HER2-Positive Gastric Cancer

Kyoung-Mee Kim, S. Park, Kyoung-Mee Kim, 2015, Scientific Reports.

Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma.

A. Bass, Kwok-Kin Wong, Shouyong Peng, 2014, The Journal of clinical investigation.

Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series

Su Jin Lee, Hyo Song Kim, S. Park, 2015, BMC Cancer.

Prognostic Model to Predict Survival Outcome for Curatively Resected Liposarcoma: A Multi-Institutional Experience

Young Han Lee, Hyo Song Kim, S. Park, 2016, Journal of Cancer.

High-Dose Ifosfamide as Second- or Third-Line Chemotherapy in Refractory Bone and Soft Tissue Sarcoma Patients

Joon-Oh Park, Jeeyun Lee, Soo Hyeon Lee, 2011, Oncology.

Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer

Joon-Oh Park, A. Bass, S. Park, 2018, Nature Medicine.

Abstract CT007: Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-naïve patients with advanced solid tumors harboring gene rearrangements: Updated phase I results

A. Drilon, A. Shaw, S. Ou, 2016 .

KIT amplification and gene mutations in acral/mucosal melanoma in Korea

E. J. Lee, Kyoung-Mee Kim, K. Jang, 2011, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

NanoString expression profiling identifies candidate biomarkers of RAD001 response in metastatic gastric cancer

Bin Tean Teh, Kyoung-Mee Kim, B. Teh, 2016, ESMO Open.

Abstract B001: Safety and efficacy of ZW25, a HER2-targeted bispecific antibody, in combination with chemotherapy in patients with locally advanced and/or metastatic HER2-expressing gastroesophageal cancer

J. Ajani, J. Mayordomo, F. Meric-Bernstam, 2019 .

Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients

Hyun Cheol Chung, Sun Young Rha, Jae Won Yun, 2018, Cancer research and treatment : official journal of Korean Cancer Association.

Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy

Joon-Oh Park, S. Park, Kyoung-Mee Kim, 2017, Oncotarget.

Moving molecular subtypes to the clinic in gastric cancer.

Jeeyun Lee, J. Chao, S. Klempner, 2016, Translational cancer research.

Genomic landscape of synchronous tubulovillous adenoma and multiple non-familial colon cancers from a single patient.

Jeeyun Lee, Won-Suk Lee, Kyung Kim, 2019, Cancer genetics.

Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer

Joon-Oh Park, S. Park, K. S. Jung, 2017, Molecular and clinical oncology.

Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas

Johann A. Gagnon-Bartsch, Y. Miyagi, T. Speed, 2014, Gut.

Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target

James X. Sun, P. Stephens, V. Miller, 2016, Clinical Cancer Research.

The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis

Joon-Oh Park, Y. Park, Y. Cho, 2016, BMC Cancer.

Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial

Joon-Oh Park, S. Park, Young Saing Kim, 2019 .

The Impact of Cetuximab Plus AKT- or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation

Joon-Oh Park, Ju Sun Kim, Kyung Kim, 2017, Journal of Cancer.

Prevalence and detection of low-allele-fraction variants in clinical cancer samples

Jeong Eon Lee, P. Park, H. Kim, 2017, Nature Communications.

TP53-dependence on the effect of doxorubicin and Src inhibitor combination therapy

D. Nam, W. Park, Jeeyun Lee, 2018, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

ADAR-Mediated RNA Editing Predicts Progression and Prognosis of Gastric Cancer.

D. Tenen, B. Teh, S. Rozen, 2016, Gastroenterology.

The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors

Joon-Oh Park, Keunchil Park, S. Park, 2016, Oncotarget.

ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma

Z. Modrušan, Tae Won Kim, Matthew T. Chang, 2021, Nature.

Impact of KRAS Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy

Joon-Oh Park, S. Park, Yoon-La Choi, 2011, Molecular Cancer Therapeutics.

Aberrant CDK4 Amplification in Refractory Rhabdomyosarcoma as Identified by Genomic Profiling

Kyoohyoung Rho, Jhingook Kim, Kyoung-Mee Kim, 2014, Scientific Reports.

Detection of ERBB2 (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient Cohort

Y. Shiotsu, Kyoung-Mee Kim, Jeeyun Lee, 2019, Front. Oncol..

c‐MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival

Su Jin Lee, Joon-Oh Park, S. Park, 2018, Clinical colorectal cancer.

Activated cMET and IGF1R-Driven PI3K Signaling Predicts Poor Survival in Colorectal Cancers Independent of KRAS Mutational Status

Joon-Oh Park, H. Kim, Anne Kuller, 2014, PloS one.

MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas

Joon-Oh Park, S. Ou, C. Park, 2013, Modern Pathology.

GSTT1 Copy Number Gain and ZNF Overexpression Are Predictors of Poor Response to Imatinib in Gastrointestinal Stromal Tumors

Kyoung-Mee Kim, Cheol Keun Park, Sung Kim, 2013, PloS one.

Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer

Joon-Oh Park, J. Ahn, Keunchil Park, 2006, Cancer Chemotherapy and Pharmacology.

Liposarcoma: exploration of clinical prognostic factors for risk based stratification of therapy

Joon-Oh Park, Hyo Song Kim, Yoon-La Choi, 2009, BMC Cancer.

Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial

R. Cristescu, D. Sinn, W. Kang, 2022, Genome Medicine.

Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial

Su Jin Lee, R. Cristescu, D. Sinn, 2022, Genome medicine.

Overexpression of MAPK15 in gastric cancer is associated with copy number gain and contributes to the stability of c-Jun

Joobae Park, Duk-Hwan Kim, Kyoung-Mee Kim, 2015, Oncotarget.

Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA–Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis

Joon-Oh Park, Keunchil Park, S. Park, 2017, JCO precision oncology.

Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project

J. Ajani, Ju-Seog Lee, J. Cheong, 2017, Clinical Cancer Research.

Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients

Joon-Oh Park, H. Kim, S. Wong, 2019, Scientific Reports.

The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer

Su Jin Lee, Joon-Oh Park, S. Park, 2019, Journal of Cancer.

Baseline neutrophil–lymphocyte ratio and platelet–lymphocyte ratio in rectal cancer patients following neoadjuvant chemoradiotherapy

H. Kim, W. Lee, Jeeyun Lee, 2018, Tumori.

Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment

Joon-Oh Park, Y. Cho, S. Park, 2020, Therapeutic advances in medical oncology.

Anti-programmed death ligand 1 (PD-L1) inhibitors in metastatic gastric cancer

J. Cho, Jeeyun Lee, 2017 .

Antitumor activity and safety of sirolimus for solid tumors with PIK3CA mutations: A multicenter, open-label, prospective single-arm study (KM 02-01, KCSG UN17-16)

Jeeyun Lee, Y. J. Kim, S. Kim, 2020, Translational cancer research.

PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA

Joon-Oh Park, Shibing Deng, W. Kwon, 2015, Oncotarget.

Transcriptome analysis of CD133-positive stem cells and prognostic value of survivin in colorectal cancer.

Joon-Oh Park, H. Kim, I. Sohn, 2014, Cancer genomics & proteomics.

A survey of c-MET expression and amplification in 287 patients with hepatocellular carcinoma.

Su Jin Lee, I. Sohn, C. Park, 2013, Anticancer research.

Safety and Efficacy of Adjuvant Chemoradiation Therapy With Capecitabine After Resection of Pancreatic Ductal Adenocarcinoma: A Retrospective Review

S. Choi, D. Choi, J. K. Lee, 2012, American journal of clinical oncology.

Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma

Jin-Hee Ahn, Jeeyun Lee, S. Rha, 2012, Cancer Chemotherapy and Pharmacology.

A Novel Proteomics-Based Clinical Diagnostics Technology Identifies Heterogeneity in Activated Signaling Pathways in Gastric Cancers

Joon-Oh Park, S. Park, Kyoung-Mee Kim, 2013, PloS one.

Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.

Myung Ah Lee, Joon-Oh Park, S. Park, 2012, The Lancet. Oncology.

Response Evaluation after Neoadjuvant Chemoradiation by Positron Emission Tomography-Computed Tomography for Esophageal Squamous Cell Carcinoma

J. Choi, Y. Shim, Jeeyun Lee, 2013, Cancer research and treatment : official journal of Korean Cancer Association.

Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor–Amplified Gastroesophageal Cancer: Retrospective Global Experience

Y. Janjigian, G. Ku, Z. Wainberg, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer

Joon-Oh Park, S. Park, I. Kozarewa, 2021, Clinical Cancer Research.

Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors

Joon-Oh Park, S. Park, Kyoung-Mee Kim, 2021, Therapeutic advances in medical oncology.

Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody

K. Jang, Kyung Kim, Jeeyun Lee, 2019, BMC Cancer.

FGFR2‐Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape

V. Miller, Siraj M. Ali, R. Madison, 2019, The oncologist.

Intratumor heterogeneity inferred from targeted deep sequencing as a prognostic indicator

Y. Park, Y. Cho, S. Yun, 2019, Scientific Reports.

Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer.

James X. Sun, P. Stephens, V. Miller, 2016, The oncologist.

Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening

Joon-Oh Park, P. Stephens, J. Huh, 2015, Oncotarget.

Antitumor Effect of AZD4547 in a Fibroblast Growth Factor Receptor 2–Amplified Gastric Cancer Patient–Derived Cell Model1

S. Park, Kyoung-Mee Kim, Jeeyun Lee, 2017, Translational oncology.

A nCounter CNV Assay to Detect HER2 Amplification: A Correlation Study with Immunohistochemistry and In Situ Hybridization in Advanced Gastric Cancer

Sin-Ho Jung, S. Park, Kyoung-Mee Kim, 2016, Molecular Diagnosis & Therapy.

Nilotinib in patients with metastatic melanoma harboring KIT gene aberration

Jin Hyun Cho, Kyoung-Mee Kim, Jeeyun Lee, 2012, Investigational New Drugs.

Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study

Young Suk Park, Joong Bae Ahn, Jae Ho Byun, 2009, Cancer Chemotherapy and Pharmacology.

Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions

Joon-Oh Park, D. V. Von Hoff, Y. Fong, 2020, Genome medicine.

The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs

Joon-Oh Park, S. Park, Kyoung-Mee Kim, 2016, Journal of Cancer.

Multiplex mutation screening by mass spectrometry in gastrointestinal stromal tumours

Joon-Oh Park, C. Park, Kyoung-Mee Kim, 2012, Pathology.

Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center’s experiences

Joon-Oh Park, M. Ahn, Keunchil Park, 2017, Oncotarget.

Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma

Zhou Zhu, Shibing Deng, P. Rejto, 2013, Hepatology.

Identification of ROS1 rearrangement in gastric adenocarcinoma

S. Ou, Jeonghee Cho, Kyoung-Mee Kim, 2013, Cancer.

Small Molecule Therapeutics Pazopanib , a Novel Multitargeted Kinase Inhibitor , Shows Potent In Vitro Antitumor Activity in Gastric Cancer Cell Lines with FGFR 2 Ampli fi cation

Su Jin Lee, Joon-Oh Park, S. Park, 2014 .

Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort

Dae-Ho Lee, Jeeyun Lee, T. Kim, 2016, Cancer research and treatment : official journal of Korean Cancer Association.

Efficacy of BRAF Inhibitors in Asian Metastatic Melanoma Patients: Potential Implications of Genomic Sequencing in BRAF-Mutated Melanoma12

W. Park, K. Jang, Kyung Kim, 2016, Translational oncology.

HER2‐positive gastric cancer with concomitant MET and/or EGFR overexpression: A distinct subset of patients for dual inhibition therapy

Sung Kim, Joon-Oh Park, S. Park, 2015, International journal of cancer.

A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis

Tae Won Kim, J. Jo, Jeeyun Lee, 2013, Investigational New Drugs.

Genetic Aberrations in Imatinib-Resistant Dermatofibrosarcoma Protuberans Revealed by Whole Genome Sequencing

Xiao Liu, Miao Li, Jeeyun Lee, 2013, PloS one.

A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study.

Joon-Oh Park, D. Doval, S. Thongprasert, 2012, European journal of cancer.

Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer

Joon-Oh Park, J. Heo, I. Han, 2021, Therapeutic advances in medical oncology.

Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan

Su Jin Lee, Joon-Oh Park, H. Kim, 2015, BMC Cancer.

Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy

Joon-Oh Park, D. Chang, Y. Cho, 2010, Cancer Chemotherapy and Pharmacology.

Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus

In Seok Yang, Min Goo Lee, Hyo Song Kim, 2016, Oncotarget.

Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab

Joon-Oh Park, Y. Cho, S. Yun, 2014, Investigational New Drugs.

Safety and anti-tumor effects of vismodegib in patients with refractory advanced gastric cancer: A single-arm, phase-II trial

Jeeyun Lee, H. Lim, S. Kim, 2022, Journal of Cancer.

Whole-Genome and Transcriptome Sequencing Identified NOTCH2 and HES1 as Potential Markers of Response to Imatinib in Desmoid Tumor (Aggressive Fibromatosis): A Phase II Trial Study

Young Han Lee, Hyo Song Kim, J. Choi, 2021, Cancer research and treatment.

Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trial

Kyoung-Mee Kim, Kyung Kim, Jeeyun Lee, 2021, Genome medicine.

Prognostic significance of sarcopenia in microsatellite-stable gastric cancer patients treated with programmed death-1 inhibitors

I. Sohn, Kyoung-Mee Kim, Jae-Hun Kim, 2020, Gastric Cancer.

Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer

S. Park, Kyoung-Mee Kim, Jeeyun Lee, 2020, Frontiers in Oncology.

Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial

Myung Ah Lee, Joon-Oh Park, Jeeyun Lee, 2019, Journal of Cancer.

The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma

Su Jin Lee, Joon-Oh Park, S. Park, 2019, Journal of Cancer.

The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma

Su Jin Lee, Joon-Oh Park, S. Park, 2019, Journal of Cancer.

Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer

S. Park, Jeeyun Lee, H. Lim, 2018, Cancer Chemotherapy and Pharmacology.

Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma

Leah M Chase, Jeeyun Lee, D. Catenacci, 2019, Clinical Cancer Research.

Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells

Su Jin Lee, S. Park, H. Sung, 2020, International journal of molecular sciences.

Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma

Y. Bang, P. Enzinger, Z. Wainberg, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Aggressive clinical course of extramammary Paget disease after radiotherapy

E. Cho, Jeeyun Lee, W. Park, 2014, Radiation oncology journal.

Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer.

Yoon Young Choi, H. Grabsch, M. Nankivell, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MSI-GC-01: Individual patient data (IPD) meta-analysis of microsatellite instability (MSI) and gastric cancer (GC) from four randomized clinical trials (RCTs).

Yoon Young Choi, H. Grabsch, M. Nankivell, 2019, Journal of Clinical Oncology.

Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.

Joon-Oh Park, Jeeyun Lee, W. Kang, 2011, Journal of the National Cancer Institute.

RRAD expression in gastric and colorectal cancer with peritoneal carcinomatosis

Joon-Oh Park, Kyoung-Mee Kim, Jeeyun Lee, 2019, Scientific Reports.

Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors

H. Kim, Kyoung-Mee Kim, J. Heo, 2015, Oncotarget.

Phase I clinical trial of KML001 monotherapy in patients with advanced solid tumors

Joon-Oh Park, J. Ahn, M. Ahn, 2020, Expert Opinion on Investigational Drugs.

Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer

S. Choi, Joon-Oh Park, I. Hwang, 2007, Cancer Chemotherapy and Pharmacology.

Validation of the Combined Biomarker for Prediction of Response to Checkpoint Inhibitor in Patients with Advanced Cancer

Kyoung-Mee Kim, Jeeyun Lee, Y. Heo, 2021, Cancers.

Correlation between MEK signature and Ras gene alteration in advanced gastric cancer

S. Park, J. Dry, D. Hodgson, 2017, Oncotarget.

Pembrolizumab (pembro) in microsatellite instability-high (MSI-H) advanced gastric/gastroesophageal junction (G/GEJ) cancer by line of therapy.

Y. Bang, C. Fuchs, J. Tabernero, 2020 .

Metastasis of Neuroendocrine Tumors Are Characterized by Increased Cell Proliferation and Reduced Expression of the ATM Gene

H. Kim, W. Lee, E. J. Lee, 2012, PloS one.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Reproduction of molecular subtypes of gastric adenocarcinoma by transcriptome sequencing of archival tissue

Kyoung-Mee Kim, Jeeyun Lee, Y. Heo, 2019, Scientific Reports.

Effect of paclitaxel/carboplatin salvage chemotherapy in noncutaneous versus cutaneous metastatic melanoma

Su Jin Lee, Young Saing Kim, W. Chang, 2013, Melanoma research.

Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplification.

Joon-Oh Park, S. Park, Kyoung-Mee Kim, 2019, American journal of translational research.

Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion

S. Park, W. Park, T. Ahn, 2017, Oncotarget.

Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin)

Su Jin Lee, Joon-Oh Park, S. Park, 2016, Journal of Cancer Research and Clinical Oncology.

Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent In Vitro Antitumor Activity in Gastric Cancer Cell Lines with FGFR2 Amplification

Su Jin Lee, Joon-Oh Park, S. Park, 2012, Molecular Cancer Therapeutics.

Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study

Joon-Oh Park, D. Nam, S. Park, 2020, Targeted Oncology.

Exome Sequencing Identifies Early Gastric Carcinoma as an Early Stage of Advanced Gastric Cancer

Joon-Oh Park, S. Park, Seonwoo Kim, 2013, PloS one.

Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.

Joon-Oh Park, S. Park, D. Shin, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract 442: Repotrectinib, a next generation TRK inhibitor, overcomes TRK resistance mutations including solvent front, gatekeeper and compound mutations

A. Drilon, A. Graber, A. Shaw, 2019, Clinical Research (Excluding Clinical Trials).

EGFR Amplification in Metastatic Colorectal Cancer.

A. Bardelli, R. Yaeger, J. Hechtman, 2021, Journal of the National Cancer Institute.

Multimodal circulating tumor DNA (ctDNA) colorectal neoplasia detection assay for asymptomatic and early-stage colorectal cancer (CRC).

H. Kim, A. Jaimovich, Jeeyun Lee, 2021 .

Detection of Fusion Genes Using a Targeted RNA Sequencing Panel in Gastrointestinal and Rare Cancers

Su Jin Lee, Joon-Oh Park, S. Park, 2020, Journal of oncology.

Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation

Joon-Oh Park, S. Park, Kyung Kim, 2018, Journal of Cancer.

Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer1

Joon-Oh Park, S. Park, Kyoung-Mee Kim, 2015, Translational oncology.

Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.

F. Hodi, Y. Bang, L. Chow, 2021, The Lancet. Oncology.

Nanostring-Based Multigene Assay to Predict Recurrence for Gastric Cancer Patients after Surgery

Insuk Sohn, Young Suk Park, Kyoung-Mee Kim, 2014, PloS one.

MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis

Jin Hyun Cho, Joon-Oh Park, S. Park, 2016, Oncotarget.

Comparison of Three BRAF Mutation Tests in Formalin-Fixed Paraffin Embedded Clinical Samples

Kyoung-Mee Kim, Yoon-La Choi, K. Jang, 2013, Korean journal of pathology.

A liquid biopsy signature predicts treatment response to fluoropyrimidine plus platinum therapy in patients with metastatic or unresectable gastric cancer: implications for precision oncology

Joon-Oh Park, Xiwei Wu, Jeeyun Lee, 2022, Molecular cancer.

A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors

Yeon-Hee Park, B. Keam, Jeeyun Lee, 2021, Investigational New Drugs.

Successful use of pazopanib for treatment of refractory metastatic hemangiopericytoma

Su Jin Lee, S. Park, Yoon-La Choi, 2014, Clinical Sarcoma Research.

High-Throughput Mutation Profiling Identifies Frequent Somatic Mutations in Advanced Gastric Adenocarcinoma

Joon-Oh Park, E. Palescandolo, L. Macconaill, 2012, PloS one.

Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06).

I. Hwang, K. Jang, Jeeyun Lee, 2015, The oncologist.

Gastric leptomeningeal carcinomatosis: multi-center retrospective analysis of 54 cases.

I. Hwang, Hyo-jin Kim, Jeeyun Lee, 2009, World journal of gastroenterology.

Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer

Joon-Oh Park, S. Park, K. Jang, 2015, Translational oncology.

MerTK is a novel therapeutic target in gastric cancer

Joon-Oh Park, S. Park, Jeonghee Cho, 2015, Oncotarget.

An investigation of the role of gene copy number variations in sorafenib sensitivity in metastatic hepatocellular carcinoma patients

C. Park, Kyoung-Mee Kim, J. Lee, 2017, Journal of Cancer.

Identification of FGFR3-TACC3 gene fusion in metastatic gastric cancer

S. Park, Kyoung-Mee Kim, Jeeyun Lee, 2017 .

Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability

S. Park, Kyoung-Mee Kim, Jeeyun Lee, 2017, Oncotarget.

Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line

Joon-Oh Park, S. Park, Kyung Kim, 2018, BMC Cancer.

The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer

Joon-Oh Park, D. Chang, Y. Cho, 2010, Medical oncology.

Delivering Cancer Care During the COVID-19 Pandemic: Recommendations and Lessons Learned From ASCO Global Webinars

Kazuhiro Yoshida, D. Kerr, R. Schilsky, 2020, JCO global oncology.

Atypical RAS Mutations in Metastatic Colorectal Cancer.

V. Miller, R. Yaeger, J. Hechtman, 2019, JCO precision oncology.

MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma—Trial in Progress.

A. Barzi, H. Lenz, J. Marshall, 2021, Journal of Clinical Oncology.

Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas

E. Cho, Seonwoo Kim, Kyoung-Mee Kim, 2013, Modern Pathology.

Oxaliplatin (3 months v 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07

S. Yun, H. Kim, W. Lee, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Loss of Tuberous Sclerosis Complex 2 (TSC2) as a Predictive Biomarker of Response to mTOR Inhibitor Treatment in Patients with Hepatocellular Carcinoma1

C. Park, Jeeyun Lee, H. Lim, 2016, Translational oncology.

Host inflammatory response predicts survival of patients with Epstein-Barr virus-associated gastric carcinoma.

C. Park, Kyoung-Mee Kim, Jeeyun Lee, 2010, Gastroenterology.

Genomic Sequencing for Bladder Urothelial Carcinoma and Its Clinical Implications for Immunotherapy

S. Park, G. Kwon, B. Jeong, 2021, Cancer research and treatment.

Metastatic lymph node in gastric cancer; Is it a real distant metastasis?

S. Park, C. Park, Jeeyun Lee, 2010, BMC Cancer.

Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel

Catalin C. Barbacioru, C. Barbacioru, M. Fakih, 2019, Clinical Cancer Research.

NTRK gene amplification in patients with metastatic cancer

Joon-Oh Park, Keunchil Park, S. Park, 2017 .

Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients

Joon-Oh Park, H. Kim, W. Lee, 2015, Oncotarget.

BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells

Su Jin Lee, O. Rath, S. Park, 2016, Translational oncology.

Effect of baseline sarcopenia on adjuvant treatment for D2 dissected gastric cancer: Analysis of the ARTIST phase III trial.

S. Park, Kyoung-Mee Kim, D. Lim, 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Prognostic Impact of Sarcopenia and Radiotherapy in Patients With Advanced Gastric Cancer Treated With Anti-PD-1 Antibody

Kyoung-Mee Kim, D. Lim, Jeeyun Lee, 2021, Frontiers in Immunology.

Serum CA19–9, cathepsin D, and matrix metalloproteinase‐7 as a diagnostic panel for pancreatic ductal adenocarcinoma

S. Choi, D. Choi, J. K. Lee, 2012, Proteomics.

A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients

Joon-Oh Park, Tae Won Kim, Jeeyun Lee, 2018, Cancer research and treatment : official journal of Korean Cancer Association.

The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer

Joon-Oh Park, S. Park, Jeeyun Lee, 2018, Journal of Cancer.

The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer

Joon-Oh Park, S. Park, Su-Jin Lee, 2017, Journal of Cancer.

A Prognostic Model to Predict Clinical Outcomes with First-Line Gemcitabine-Based Chemotherapy in Advanced Pancreatic Cancer

S. Choi, D. Choi, J. K. Lee, 2011, Oncology.

Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing

Jason G. Jin, Joon-Oh Park, H. Dai, 2014, Nature Communications.

A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor‐Induced Skin Toxicities

Young Saing Kim, M. Roh, I. Hwang, 2019, The oncologist.

Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial

R. Plummer, B. Melichar, Yoon-Koo Kang, 2019, Journal of Immunotherapy for Cancer.

Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram

S. Park, L. Antonuzzo, R. Miceli, 2018, Oncology.

Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab

M. Choi, Jeeyun Lee, H. Lim, 2020, Cancer Immunology, Immunotherapy.

Erratum: Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab (Investigational New Drugs (2014) 32 (535-541) DOI: 10.1007/s10637-014-0065-x)

Joon-Oh Park, Y. Cho, S. Yun, 2014 .

Changes in the Mean Corpuscular Volume after Capecitabine Treatment Are Associated with Clinical Response and Survival in Patients with Advanced Gastric Cancer

Joon-Oh Park, S. Park, Jeeyun Lee, 2014, Cancer research and treatment : official journal of Korean Cancer Association.

Which Patients Benefit from Preoperative Chemoradiotherapy for Intermediate Staged Rectal Cancer?

Joon-Oh Park, Y. Cho, S. Yun, 2011, Oncology Research and Treatment.

High-Throughput Genotyping in Metastatic Esophageal Squamous Cell Carcinoma Identifies Phosphoinositide-3-Kinase and BRAF Mutations

Kyoung-Mee Kim, Paul van Hummelen, So Young Kang, 2012, PloS one.

Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03.

Y. Janjigian, Keun-Wook Lee, Y. Chao, 2022, Journal of Clinical Oncology.

Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1–positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial.

E. Van Cutsem, J. Tabernero, Z. Wainberg, 2022, Journal of Clinical Oncology.

Prognostic Impact of Microsatellite Instability in Asian Gastric Cancer Patients Enrolled in the ARTIST Trial

S. Park, R. Miceli, Kyoung-Mee Kim, 2019, Oncology.

Association of Tumor Mutational Burden with Efficacy of Pembrolizumab{plus minus}Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study.

Y. Bang, E. Van Cutsem, J. Tabernero, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Prognostic and predictive value of metabolic tumor volume on 18F-FDG PET/CT in advanced biliary tract cancer treated with gemcitabine/oxaliplatin with or without erlotinib

S. Choi, D. Choi, J. K. Lee, 2014, Medical Oncology.

Computational measurement of tumor immune microenvironment in gastric adenocarcinomas

Y. Chang, Kyoung-Mee Kim, Jeeyun Lee, 2018, Scientific Reports.

Trastuzumab Deruxtecan in Anti–Human Epidermal Growth Factor Receptor 2 Treatment–Naive Patients With Human Epidermal Growth Factor Receptor 2–Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial

Y. Bang, N. Sugimoto, Keun-Wook Lee, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of four immunohistochemical tests and FISH for measuring Her2 expression in gastric carcinomas

E. Cho, Kyoung-Mee Kim, I. Do, 2012, Pathology.

Towards the goal of personalized medicine in gastric cancer--time to move beyond HER2 inhibition. Part II: Targeting gene mutations and gene amplifications and the angiogenesis pathway.

S. Ou, Jeeyun Lee, 2013, Discovery medicine.

Towards the goal of personalized medicine in gastric cancer--time to move beyond HER2 inhibition. Part I: Targeting receptor tyrosine kinase gene amplification.

S. Ou, Jeeyun Lee, Jeeyun Lee, 2013, Discovery medicine.

Abstract CT111: Avelumab (anti-PD-L1) as first-line maintenance (1L mn) or second-line (2L) therapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC): updated phase Ib results from the JAVELIN Solid Tumor trial

R. Plummer, B. Melichar, Yoon-Koo Kang, 2018, Clinical Trials.

ARTIST 2: Interim results of a phase III trial involving adjuvant chemotherapy and/or chemoradiotherapy after D2-gastrectomy in stage II/III gastric cancer (GC).

S. Park, I. Hwang, Kyoung-Mee Kim, 2019, Journal of Clinical Oncology.

Genetic Polymorphisms Associated with 5-Fluorouracil-Induced Neurotoxicity

Joon-Oh Park, Soo-Youn Lee, Jeeyun Lee, 2010, Chemotherapy.

Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in MET-Amplified Gastric Cancer

J. Barrett, S. Park, Kyoung-Mee Kim, 2020, JCO precision oncology.

Association Between Spatial Heterogeneity Within Nonmetastatic Gastroesophageal Adenocarcinomas and Survival

Yate-Ching Yuan, P. Chu, Jeeyun Lee, 2020, JAMA network open.

A Pilot Study of Baseline Spatial Genomic Heterogeneity in Primary Gastric Cancers Using Multi-Region Endoscopic Sampling

Kyoung-Mee Kim, Jeeyun Lee, Hyuk Lee, 2020, Frontiers in Oncology.

Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform

J. Ajani, J. Lacy, C. Lopez, 2023, The oncologist.

Molecular characterization of colorectal cancer patients and concomitant patient-derived tumor cell establishment

Joon-Oh Park, Y. Park, Y. Cho, 2016, Oncotarget.

Pemetrexed/Erlotinib as a Salvage Treatment in Patients with High EGFR-Expressing Metastatic Colorectal Cancer Following Failure of Standard Chemotherapy: A Phase II Single-Arm Prospective Study

Joon-Oh Park, Jeeyun Lee, S. Kim, 2019, Targeted Oncology.

Pemetrexed Monotherapy as Salvage Treatment in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy: A Phase II Single-arm Prospective Trial

Joon-Oh Park, S. Park, Jeeyun Lee, 2018, Journal of Cancer.

Abstract 916: Combined genomic and epigenomic assessment of cell-free circulating tumor DNA (ctDNA) improves assay sensitivity in early-stage colorectal cancer (CRC)

Joon-Oh Park, H. Kim, E. Zotenko, 2019, Clinical Research (Excluding Clinical Trials).

Combined biomarker for prediction of response to an immune checkpoint inhibitor in metastatic gastric cancer

Kyoung-Mee Kim, Jeeyun Lee, S. Kim, 2019 .

Phase I Trial of Anti‐MET Monoclonal Antibody in MET‐Overexpressed Refractory Cancer

Joon-Oh Park, M. Ahn, S. Park, 2018, Clinical colorectal cancer.

Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062

T. Yoshikawa, K. Lam, K. Yeh, 2022, Japanese Journal of Clinical Oncology.

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01).

Y. Bang, N. Sugimoto, D. Sakai, 2021 .

Abstract OT-03-02: Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors

Michael N. Alonso, E. Perez, D. Juric, 2021 .

Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis

S. Park, Tae Won Kim, H. Kang, 2013, Cancer Chemotherapy and Pharmacology.

Definitive chemoradiation therapy with capecitabine in locally advanced pancreatic cancer

S. Choi, D. Choi, J. K. Lee, 2009, Anti-cancer drugs.

Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial

Y. Miyagi, Kazuhiro Yoshida, H. Grabsch, 2021, Gut.

Impact of Prior Ramucirumab Use on Treatment Outcomes of Checkpoint Inhibitors in Advanced Gastric Cancer Patients

Jeeyun Lee, H. Lim, S. Kim, 2020, Targeted Oncology.

Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study

Su Jin Lee, Yeon-Hee Park, S. Park, 2015, BMC Cancer.

Phase 1a study results investigating the safety and preliminary efficacy of ABL001 (NOV1501), a bispecific antibody targeting VEGF and DLL4 in metastatic gastrointestinal (GI) cancer.

Joon-Oh Park, S. Park, W. You, 2019, Journal of Clinical Oncology.

Safety and preliminary clinical activity of the MET antibody mixture, Sym015 in advanced non-small cell lung cancer (NSCLC) patients with MET amplification/exon 14 deletion (METAmp/Ex14∆).

R. Heist, E. Felip, A. Navarro, 2020 .

Xerna™ TME Panel is a machine learning-based transcriptomic biomarker designed to predict therapeutic response in multiple cancers

Rafael D. Rosengarten, Jeeyun Lee, M. Uhlik, 2023, Frontiers in Oncology.

Abstract 1232: Xerna࣪ TME Panel: A pan-cancer RNA-based investigational assay designed to predict patient responses to angiogenic and immune targeted therapies

Rafael D. Rosengarten, Jeeyun Lee, M. Uhlik, 2022, Cancer Research.

Chromatin accessibility of circulating CD8+ T cells predicts treatment response to PD-1 blockade in patients with gastric cancer

S. Cho, J. Choi, S. Ye, 2021, Nature Communications.

The efficacy of the frontline platinum-based combination chemotherapy in malignant peritoneal mesothelioma.

Joon-Oh Park, S. Park, Jeeyun Lee, 2010, Japanese journal of clinical oncology.

The Efﬁcacy of the Frontline Platinum-based Combination Chemotherapy in Malignant Peritoneal Mesothelioma

Joon-Oh Park, S. Park, Jeeyun Lee, 2010 .

Comparison of the 7th and the 8th AJCC Staging System for Non-metastatic D2-Resected Lymph Node–Positive Gastric Cancer Treated with Different Adjuvant Protocols

Su Jin Lee, Joon-Oh Park, S. Park, 2018, Cancer research and treatment : official journal of Korean Cancer Association.

INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC)--A study by the Australasian Gastrointestinal Trials Group (AGITG), first results.

L. Lipton, N. Pavlakis, Y. Bang, 2015 .

MET is overexpressed in microsatellite instability-high gastric carcinoma.

Kyoung-Mee Kim, Jeeyun Lee, Hyeong Chan Shin, 2019, Pathology, research and practice.

TPK1 as a predictive marker for the anti-tumour effects of simvastatin in gastric cancer.

Joon-Oh Park, S. Park, Kyoung-Mee Kim, 2020, Pathology, research and practice.

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors

A. Drilon, G. Demetri, T. Wilson, 2022, Clinical Cancer Research.

To Excavate Biomarkers Predictive of the Response for Capecitabine plus RAD001 through Nanostring-Based Multigene Assay in Advanced Gastric Cancer Patients

Joon-Oh Park, I. Sohn, S. Park, 2016, Journal of Cancer.

One-step achievement of tumor spheroid-induced angiogenesis in a high-throughput microfluidic platform: one-step tumor angiogenesis platform

N. Jeon, Jihoon Ko, Jeeyun Lee, 2023, Organoid.

Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer

Su Jin Lee, Joon-Oh Park, Sin-Ho Jung, 2015, Oncotarget.

Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody

Su Jin Lee, K. Jang, Kyung Kim, 2019, BMC Cancer.

Necessity of adjuvant concurrent chemo-radiotherapy in D2-resected LN-positive gastric cancer.

Su Jin Lee, Joon-Oh Park, S. Park, 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer

Su Jin Lee, Joon-Oh Park, S. Park, 2018, Translational oncology.

Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study

Su Jin Lee, Yeon-Hee Park, S. Park, 2015, BMC Cancer.

High-Throughput Sequencing and Copy Number Variation Detection Using Formalin Fixed Embedded Tissue in Metastatic Gastric Cancer

S. Park, Duk-Hwan Kim, Kyoung-Mee Kim, 2014, PloS one.

Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study

Yeul-Hong Kim, Jeeyun Lee, H. Lim, 2017, Cancer research and treatment : official journal of Korean Cancer Association.

SSTR2A Protein Expression in Neuroendocrine Neoplasms of the Colorectum

Kyoung-Mee Kim, Jeeyun Lee, Y. Park, 2011 .

Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial

Joon-Oh Park, S. Park, Kyoung-Mee Kim, 2019, Translational oncology.

Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + PEGPH20 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).

J. Ajani, J. Lacy, Y. Bang, 2020, Journal of Clinical Oncology.

Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + BL-8040 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).

J. Ajani, J. Lacy, Y. Bang, 2020, Journal of Clinical Oncology.

MORPHEUS: A phase Ib/II study platform evaluating the safety and clinical efficacy of cancer immunotherapy (CIT)–based combinations in gastrointestinal (GI) cancers.

J. Desai, N. Segal, M. Fakih, 2019, Journal of Clinical Oncology.

Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy

Joon-Oh Park, S. Park, Jeeyun Lee, 2017, BMC Cancer.

Clinical Application of Targeted Deep Sequencing in Solid-Cancer Patients and Utility for Biomarker-Selected Clinical Trials.

Joon-Oh Park, P. Park, H. Kim, 2017, The oncologist.

A nCounter CNV Assay to Detect HER2 Amplification: A Correlation Study with Immunohistochemistry and In Situ Hybridization in Advanced Gastric Cancer

Sin-Ho Jung, S. Park, Kyoung-Mee Kim, 2016, Molecular Diagnosis & Therapy.

The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis

Joon-Oh Park, H. Kim, J. Ahn, 2015, Oncotarget.

Expression of activated signal transducer and activator of transcription 3 predicts poor clinical outcome in gastric adenocarcinoma

Joon-Oh Park, S. Park, C. Park, 2009, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

The Right Treatment of the Right Patient: Integrating Genetic Profiling Into Clinical Decision Making in Advanced Gastric Cancer in Asia.

Jeeyun Lee, K. Shitara, Y. Nakamura, 2021, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line

Joon-Oh Park, S. Park, Kyung Kim, 2018, BMC Cancer.

Transcriptional analysis of immune genes in Epstein–Barr virus-associated gastric cancer and association with clinical outcomes

B. Teh, P. Tan, Kyoung-Mee Kim, 2018, Gastric Cancer.

Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes.

B. Teh, P. Tan, Kyoung-Mee Kim, 2018 .

Prospective phase II trial of regional hyperthermia and whole liver irradiation for numerous chemorefractory liver metastases from colorectal cancer

Joon-Oh Park, S. Park, Jeeyun Lee, 2016, Radiation oncology journal.

FGFR3-TACC3: A novel gene fusion in malignant melanoma

Su Jin Lee, S. J. Lee, J. Lee, 2018, Precision and Future Medicine.

Abstract A173: Potent anti-tumor activity of entrectinib in patient-derived models harboring oncogenic gene rearrangements of NTRKs

R. Shoemaker, A. Bardelli, Kyoung-Mee Kim, 2015 .

A Machine Learning Approach Using FDG PET-Based Radiomics for Prediction of Tumor Mutational Burden and Prognosis in Stage IV Colorectal Cancer

S. Hyun, Jeeyun Lee, S. Moon, 2023, Cancers.

MCT4 Expression Is a Potential Therapeutic Target in Colorectal Cancer with Peritoneal Carcinomatosis

Su Jin Lee, S. Yun, H. Kim, 2018, Molecular Cancer Therapeutics.

S130 Multimodal Circulating Tumor DNA (ctDNA) Blood-Based Colorectal Cancer (CRC) Screening Test Demonstrates Clinically Meaningful Sensitivity Across Multiple Clinical Parameters

H. Kim, A. Jaimovich, Jeeyun Lee, 2021, American Journal of Gastroenterology.

Prevalence and detection of low-allele-fraction variants in clinical cancer samples

P. Park, H. Kim, W. Lee, 2017, Nature Communications.

The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma

Su Jin Lee, Joon-Oh Park, S. Park, 2019, Journal of Cancer.

A phase I study of TGF-β inhibitor, vactosertib in combination with imatinib in patients with advanced desmoid tumor (aggressive fibromatosis).

Jeeyun Lee, S. Hwang, Seong-Jin Kim, 2020 .

A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis.

Tae Won Kim, J. Jo, Jeeyun Lee, 2013 .

Bridging genomics and phenomics of gastric carcinoma

Joon-Oh Park, S. Park, Kyoung-Mee Kim, 2019, International journal of cancer.

Clinical Outcomes and the Role of Adjuvant Concurrent Chemoradiation Therapy in D2-resected LN-positive Young Patients (≤45 Years) With Gastric Cancer

Joon-Oh Park, S. Park, D. Lim, 2019, AntiCancer Research.

IKKε and TBK1 expression in gastric cancer

Kyoung-Mee Kim, M. Hong, Jeeyun Lee, 2016, Oncotarget.

First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients.

Joon-Oh Park, D. Nam, S. Park, 2018 .

Outcomes of Radiotherapy for Mesenchymal and Non-Mesenchymal Subtypes of Gastric Cancer

S. Park, Kyoung-Mee Kim, D. Lim, 2020, Cancers.

Prognostic Factors of Survival with Aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as Second-line Therapy for Patients with Metastatic Colorectal Cancer

Joon-Oh Park, S. Park, Jeeyun Lee, 2021, Journal of Cancer.

Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer

H. Kim, S. Lim, Jeeyun Lee, 2023, Oncology research.

PIK3CA mutation subtype delineates distinct immune profiles in gastric carcinoma

Kyoung-Mee Kim, Jeeyun Lee, Hyunjin Kim, 2023, The Journal of pathology.

Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Digoxin in Patients With BRAFV600 Mutation–Positive Metastatic Malignancy

L. Demidov, Jeeyun Lee, T. Kim, 2018, Journal of clinical pharmacology.

Coexistence of EBV associated nasopharyngeal undifferentiated carcinoma and gastric lymphoepithelioma-like carcinoma.

Sun‐mi Lee, Y. Ko, Kyoung-Mee Kim, 2010, Pathology.

The Optimal Tumor Mutational Burden Cutoff Value as a Novel Marker for Predicting the Efficacy of Programmed Cell Death-1 Checkpoint Inhibitors in Advanced Gastric Cancer

S. Lim, Jeeyun Lee, S. Jeong, 2023, Journal of gastric cancer.

The Influence of Metastatic Lymph Node Ratio on the Treatment Outcomes in the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Trial: A Phase III Trial

Su Jin Lee, Joon-Oh Park, S. Park, 2016, Journal of gastric cancer.

Joon-Oh Park, I. Sohn, Sin-Ho Jung, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

99mTc-MIBI uptake as a marker of mitochondrial membrane potential in cancer cells and effects of MDR1 and verapamil

Kyung-Han Lee, Jeeyun Lee, Kyung-Ho Jung, 2020, PloS one.

Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition

S H Lee, W. Park, Jeeyun Lee, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

ADAR-Mediated RNA Editing Predicts Progression and Prognosis of Gastric Cancer.

D. Tenen, B. Teh, S. Rozen, 2016, Gastroenterology.

Circulating Tumor Cells are Predictive of Poor Response to Chemotherapy in Metastatic gastric cancer

Su Jin Lee, Joon-Oh Park, S. Park, 2015, International Journal of Biological Markers.

The efficacy of the frontline platinum-based combination chemotherapy in malignant peritoneal mesothelioma.

Joon-Oh Park, S. Park, Jeeyun Lee, 2010, Japanese journal of clinical oncology.

Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative-Intent Surgery and/or Ablation for Metastatic Rectal Cancer

Joon-Oh Park, J. Huh, Y. Park, 2022, Annals of Surgical Oncology.

Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.

Joon-Oh Park, Jeeyun Lee, W. Kang, 2011, Journal of the National Cancer Institute.

Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine (a CYP1A2 Substrate) in Patients With BRAFV600 Mutation–Positive Malignancies

Dae-Ho Lee, Jeeyun Lee, H. Choi, 2020, Clinical pharmacology in drug development.

Multicenter phase III trial of adjuvant chemoradiotherapy in stomach tumors 2 (ARTIST 2).

Su Jin Lee, Joon-Oh Park, S. Park, 2015 .

Treatment of Hemodialyzed Patients with Sunitinib in Renal Cell Carcinoma

Jin Hyun Cho, Joon-Oh Park, S. Park, 2010, Chemotherapy.

Impact of Radiotherapy on Kidney Function among Patients Who Received Adjuvant Treatment for Gastric Cancer: Logistic and Linear Regression Analyses

S. Park, D. Lim, Jeeyun Lee, 2020, Cancers.

Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma.

A. Bass, Shouyong Peng, A. Thorner, 2014, The Journal of clinical investigation.

Prevalence of RAF1 Aberrations in Metastatic Cancer Patients: Real-World Data

Joon-Oh Park, Jeeyun Lee, Seung-Tae Kim, 2023, Biomedicines.

Adjuvant Chemotherapy Versus Chemoradiotherapy Versus Surgery Alone for Early Gastric Cancer with One or Two Lymph Node Metastasis

Jeeyun Lee, T. Sohn, Su Mi Kim, 2018, Annals of Surgical Oncology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

A phase Ib trial of belvarafenib in combination with cobimetinib in patients with advanced solid tumors: Interim results of dose-escalation and patients with NRAS-mutant melanoma of dose-expansion.

Dae-Ho Lee, Jeeyun Lee, S. Monemi, 2021 .

Prognostic and predictive impact of sex in locally advanced microsatellite instability high gastric or gastroesophageal junction cancer: An individual patient data pooled analysis of randomized clinical trials.

M. Nankivell, A. Wotherspoon, Jeeyun Lee, 2024, European journal of cancer.

Clinically conserved genomic subtypes of gastric adenocarcinoma

J. Ajani, S. Yim, B. Sohn, 2023, Molecular Cancer.

Clinical Significance of Preoperative Hematological Parameters in Patients with D2-Resected, Node-Positive Stomach Cancer

S. Park, D. Lim, Jeeyun Lee, 2022, Biomedicines.

Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy

Joon-Oh Park, S. Park, Jeeyun Lee, 2017, BMC Cancer.

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2–positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01).

Y. Bang, N. Sugimoto, D. Sakai, 2022, Journal of Clinical Oncology.

Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer

N. Schultz, D. Solit, U. Bhanot, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

HER2‐positive gastric cancer with concomitant MET and/or EGFR overexpression: A distinct subset of patients for dual inhibition therapy

Joon-Oh Park, S. Park, C. Park, 2015, International journal of cancer.

Early immune remodeling steers clinical response to frontline chemoimmunotherapy in advanced gastric cancer.

Jeeyun Lee, Y. Heo, Seung-Tae Kim, 2024, Cancer discovery.

Patient-derived tumor spheroid-induced angiogenesis preclinical platform for exploring therapeutic vulnerabilities in cancer.

Jihoon Ko, Jeeyun Lee, Y. Heo, 2024, Biomaterials.

Patient-derived exosomes facilitate therapeutic targeting of oncogenic MET in advanced gastric cancer

Joon-Oh Park, Jeeyun Lee, Y. Heo, 2023, Science Advances.

MET gene alterations predict poor survival following chemotherapy in patients with advanced cancer

Joon-Oh Park, Jihoon Ko, Kyoung-Mee Kim, 2022, Pathology & Oncology Research.

Tumor mutation burden in gastro-entero-pancreatic-neuroendocrine neoplasms

Jeeyun Lee, S. Jeong, Y. Park, 2023, Journal of gastrointestinal oncology.